Evidence map›Paper›PMID 41459502›Full record

ArticleFrontiers in immunology2025

Mono-WNV and combined WNV/TBEV inactivated vaccine efficacy against a wide range of WNV and TBEV strains.

Ksenia Tuchynskaya, Mikhail Vorovitch, Yuriy Kruglov, Guzal Mostipanova, Ivan Kholodilov, Alla Ivanova, Victoria Kuchina, Anastasia Rogova, Galina Karganova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ksenia TuchynskayaLaboratory of Biology of Arbovirus, Federal State Autonomous Scientific Institution "Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences" (Institute of Poliomyelitis), Moscow, Russia.
Mikhail VorovitchDepartment of Encephalitis Vaccine, Federal State Autonomous Scientific Institution Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Moscow, Russia.
Yuriy KruglovDepartment of Encephalitis Vaccine, Federal State Autonomous Scientific Institution Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Moscow, Russia.
Guzal MostipanovaDepartment of Encephalitis Vaccine, Federal State Autonomous Scientific Institution Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Moscow, Russia.
Ivan KholodilovLaboratory of Biology of Arbovirus, Federal State Autonomous Scientific Institution "Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences" (Institute of Poliomyelitis), Moscow, Russia.
Alla IvanovaDepartment of Encephalitis Vaccine, Federal State Autonomous Scientific Institution Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Moscow, Russia.
Victoria KuchinaLaboratory of Biology of Arbovirus, Federal State Autonomous Scientific Institution "Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences" (Institute of Poliomyelitis), Moscow, Russia.
Anastasia RogovaLaboratory of Biology of Arbovirus, Federal State Autonomous Scientific Institution "Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences" (Institute of Poliomyelitis), Moscow, Russia.
Galina KarganovaLaboratory of Biology of Arbovirus, Federal State Autonomous Scientific Institution "Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences" (Institute of Poliomyelitis), Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

West Nile virus (WNV) is widespread throughout the world. Occasionally, it causes outbreaks of the West Nile fever (WNF) disease, which can lead to severe CNS damage or death. At the same time, the virus' expanding range is increasingly leading to the formation of mixed foci with other orthoflaviviruses, such as tick-borne encephalitis virus (TBEV). Based on long-term experience using inactivated vaccines to target tick-borne encephalitis (TBE), it seems sensible to create a complex inactivated vaccine targeting two antigens to protect the population against several orthoflaviviruses at once. The immunogenicity and efficacy of the mono-WNV and combined WNV/TBEV inactivated vaccines-based on WNV strain SHUA-3 and TBEV strain Sofjin against a wide range of WNV and TBEV strains-were compared in an

Indexed as

Encephalitis, Tick-BorneEncephalitis Viruses, Tick-BorneViral VaccinesWest Nile FeverWest Nile virusWest Nile Virus VaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralFemaleHumansImmunogenicity, VaccineMiceMice, Inbred BALB CVaccine EfficacyVaccines, CombinedAntibodies, NeutralizingAntibodies, ViralVaccines, CombinedVaccines, InactivatedViral VaccinesWest Nile Virus Vaccinescombined vaccineflavivirusesinactivated vaccineorthoflavivirusesTBEVWNV

Identifiers

PMID41459502
PMCPMC12741126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.